EUVIMEDEUVIMED entdecken
Crossref

Survival Outcomes of Durvalumab in Combination with Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer: Real-World Results from a Single Italian Institution

Margherita Rimini, Silvia Foti, Silvia Camera, Federico Rossari, Francesco Vitiello, Federica Lo Prinzi, Luca Aldrighetti, Francesco De Cobelli, Federica Pedica, Paolo Giorgio Arcidiacono, Mara Persano, Stefano Cascinu und 1 weitere

Oncology · 2024

DOI: 10.1159/000541891 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology, 2024. Verfasst von Margherita Rimini und 12 weiteren Autor:innen. Beteiligte Einrichtung: Vita-Salute University San Raffaele, Milan, Italy. Hauptthemen laut MEDLINE: Deoxycytidine, Antineoplastic Combined Chemotherapy Protocols, Biliary Tract Neoplasms, Antibodies, Monoclonal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The TOPAZ-1 phase III trial showed a survival benefit with durvalumab plus gemcitabine and cisplatin in patients with advanced biliary tract cancer (BTC). To understand this combinationʼs real-world efficacy and tolerability, we conducted a retrospective analysis of its first-line treatment outcomes.

Methods

We included patients with unresectable, locally advanced, or metastatic BTC treated with cisplatin, gemcitabine, plus durvalumab. The primary endpoint was overall survival (OS).

Results

Thirty-three patients were enrolled. Median OS was NR and median progression free survival (PFS) was 7.6 months, after a median follow-up of 13.5 months. The investigator-assessed overall response rate was 34.5%, with stable disease in 53.0% of patients. High baseline CEA levels were associated with poor survival. Any grade adverse events (AEs) occurred in 97% of patients. Immune-related AEs (irAEs) occurred in 16% (grade >2: 6%). Presence of TP53 mutation was related to a worse OS; conversely the presence of ARID1A genomic alteration was related to a better PFS. A tendence toward a better OS was found for BRCAness patients which did not reach the statistical significance. On the other hand, BRCAness patients showed significantly higher PFS compared to no BRCAness patients.

Conclusion

This real-world analysis largely confirmed the TOPAZ-1 findings, supporting gemcitabine, cisplatin, and durvalumab as a first-line standard of care for patients with advanced BTC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DeoxycytidineAntineoplastic Combined Chemotherapy ProtocolsBiliary Tract NeoplasmsAntibodies, MonoclonalHumansCisplatinFemaleMaleGemcitabineMiddle AgedAgedRetrospective StudiesAdultItalyProgression-Free SurvivalAged, 80 and overTreatment Outcome

Stichwörter der Autor:innen

DurvalumabFGFR2IDHMaintenenceMolecularNeutrophil-to-lymphocyte ratio

Substanzen

CisplatinGemcitabineDeoxycytidinedurvalumabAntibodies, Monoclonal

Autor:innen und Institutionen

  • Vita-Salute University San Raffaele, Milan, Italy.
  • IRCCS San Raffaele Hospital, Oncology Department, Milan, Italy.
  • Operative Research Unit of Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
  • Oncology Department, University Hospital of Cagliari, Cagliari, Italy.

Zitieren

APA

Rimini, M., Foti, S., Camera, S., Rossari, F., Vitiello, F., Lo Prinzi, F., Aldrighetti, L., De Cobelli, F., Pedica, F., Arcidiacono, P. G., Persano, M., Cascinu, S., & Casadei-Gardini, A. (2024). Survival Outcomes of Durvalumab in Combination with Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer: Real-World Results from a Single Italian Institution. Oncology. https://doi.org/10.1159/000541891

Vancouver

Rimini M, Foti S, Camera S, Rossari F, Vitiello F, Lo Prinzi F, et al. Survival Outcomes of Durvalumab in Combination with Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer: Real-World Results from a Single Italian Institution. Oncology. 2024. doi:10.1159/000541891

BibTeX
@article{Rimini2024,
  author = {Rimini, Margherita and Foti, Silvia and Camera, Silvia and Rossari, Federico and Vitiello, Francesco and Lo Prinzi, Federica and Aldrighetti, Luca and De Cobelli, Francesco and Pedica, Federica and Arcidiacono, Paolo Giorgio and Persano, Mara and Cascinu, Stefano and Casadei-Gardini, Andrea},
  title = {Survival Outcomes of Durvalumab in Combination with Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer: Real-World Results from a Single Italian Institution},
  journal = {Oncology},
  year = {2024},
  doi = {10.1159/000541891}
}
Kostenlos starten →